DNA research concept DNA barcodes for biomedical research  mitochondrial DNA  Prostate cancer DNA test

8 Companion Diagnostic Developers Making a Mark

If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark...
Projections for the growth of the liquid biopsy market range as low as $1 billion by 2020

10 Liquid Biopsy Companies in the Money

10 privately-held diagnostics developers primarily focused on liquid biopsy tests, ranked by total money raised from venture capital firms.
Depressed woman with head in hands

UnitedHealthcare To Cover Genetic Testing for Precision Medicine in Depression, Anxiety

The nation’s largest private health insurer, UnitedHealthcare, announced August 1 that it will cover testing that will allow physicians to match their patients to...

Mining the Microbiome: Microbiome startups are proliferating, exploring new markets, and colonizing diverse therapeutic...

It would be hard to find an area of health where the microbiome has not been implicated as a major player. The microbiome is...

Small Sequencer Developer GenapSys Completes $90M Series C Financing

GenapSys’ sequencing system is about the size of an iPad, costs under $10,000, and is based on a proprietary direct electronic sequencing chip, which is intended to eliminate the need for cumbersome equipment.

PerkinElmer Genomics, U. of Iowa Develop FSHD Assay Based on Bionano’s Saphyr

Bionano Genomics announced at the American Society of Human Genetics (ASHG) annual meeting in Houston that PerkinElmer Genomics and the University of Iowa have...

Promega to Develop MSI Technology as CDx to Merck’s Keytruda

Promega’s MSI testing is designed to functionally measure the genomic accumulation of insertion or deletion (INDEL) errors caused by a deficient mismatch-repair system (dMMR) that occurs in certain types of solid tumors.
The American Association of Clinical Urologists (AACU) has issued a position statement encouraging the use of tissue-based molecular testing and/or germline testing for three groups of prostate cancer patients. [Ji-Xin Cheng

Clinical Urologists Group Supports Genomic Testing for Prostate Cancer

AACU statement encourages use of tissue-based molecular testing and/or germline testing for three groups of prostate cancer patients

Genomind Launching Enhanced Mental Health Biomarker Test

Genomind said today it will launch an enhanced version of its mental health genetic test that will feature a new, more focused report and...
Light micrograph of metastases in breast tissue

Triple Negative Breast Cancer Recurrence Prediction Method Developed

Women whose plasma contained circulating tumor DNA had only a 56% chance of being cancer-free two years following chemotherapy and surgery, while those without it had an 81% chance the cancer would not return in the same time span.
Scroll Up